- Home
- CWEN vs APLS Comparison
CWEN vs APLS Comparison
Compare CWEN & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CWEN | APLS |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | United States | United States |
| Employees | 60 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 5.2B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | CWEN | APLS |
|---|---|---|
| Price | $40.36 | $40.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 21 |
| Target Price | ★ $42.00 | $31.44 |
| AVG Volume (30 Days) | 754.8K | ★ 6.3M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.50% | N/A |
| EPS Growth | N/A | ★ 112.50 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $1,003,782,000.00 |
| Revenue This Year | $15.19 | N/A |
| Revenue Next Year | $7.78 | $18.21 |
| P/E Ratio | ★ $17.06 | $201.95 |
| Revenue Growth | N/A | ★ 28.46 |
| 52 Week Low | $25.63 | $16.10 |
| 52 Week High | $41.51 | $40.45 |
Technical Indicators
Market Signals| Indicator | CWEN | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 61.92 | 87.63 |
| Support Level | $36.78 | $19.38 |
| Resistance Level | $41.51 | N/A |
| Average True Range (ATR) | 1.09 | 0.54 |
| MACD | 0.09 | 2.78 |
| Stochastic Oscillator | 86.93 | 99.85 |
Price Performance
Historical ComparisonAbout CWEN Clearway Energy Inc. Class C
Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and the owner of modern, sustainable, and long-term contracted assets across North America. The company segments its operations into Flexible Generation, Renewables & Storage, and Corporate divisions. The majority of its revenue is generated from the Renewables & Storage segment.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).